RxDoctor Payments Data

Kathleen Jee, MD

Ophthalmology · Brecksville, OHNPI 1063751436

Payments from drug & device makers

$17,065in general payments, 2019–2025

Across 78 payments — averaging $218.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$13K
  • Carl Zeiss Meditec USA, Inc.$2K
  • Alcon$767
  • AbbVie$263
  • Tarsus Pharmaceuticals, Inc.$174
  • Glaukos Corporation$173
  • plus $630 from 13 others
$10in research payments, 2019–2025

Across 1 payment — averaging $9.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$10

What the payments were for

  • Consulting fees$2,32014%
  • Speaking & faculty fees$10,51062%
  • Travel & lodging$1,66610%
  • Food & beverage$2,56815%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,065 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$316,419
Medicare patients
597
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$60,522
LumiganBimatoprost45$20,946
XiidraLifitegrast12$13,558
Cyclosporine23$10,198
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$8,016
Latanoprost584$7,978
RhopressaNetarsudil Mesylate15$6,557
Ketorolac Tromethamine236$4,542
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat164$2,867
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha242$2,614
Brimonidine Tartrate187$2,196
Loteprednol Etabonate17$2,145
Prednisolone Acetate74$1,977
Timolol Maleate153$1,835
TafluprostTafluprost/Pf12$1,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$263$81,468126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Brecksville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →